Literature DB >> 3121759

Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections.

H V Raff1, D Devereux, W Shuford, D Abbott-Brown, G Maloney.   

Abstract

We produced human monoclonal antibody that demonstrated specific reactivity to the K1 capsule of Escherichia coli and the group B polysaccharide of Neisseria meningitidis. The antibody was nonreactive with several strains of K1- E. coli and other gram-negative bacteria. All E. coli K1 clinical isolates tested were reactive with the antibody. When assayed for in vitro opsonophagocytic ability, the antibody caused bacterial removal only in the presence of human complement and neutrophils, an observation suggesting a non-bacteriolytic, neutrophil-dependent killing mechanism. Finally, and perhaps most importantly, the antibody was highly protective for infectious disease when used prophylactically in three animal models. The data suggest a potential use for human monoclonal antibodies in preventing and/or treating infections of the blood.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3121759     DOI: 10.1093/infdis/157.1.118

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity.

Authors:  Joseph Martinez; Tamara Pilishvili; Suzanne Barnard; Joseph Caba; Willie Spear; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 3.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

4.  The potential use of monoclonal antibodies as therapeutic modalities in neonatal infection.

Authors:  H R Hill; L A Gonzales; D K Kelsey; H V Raff
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

5.  Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine.

Authors:  A Aase; G Bjune; E A Høiby; E Rosenqvist; A K Pedersen; T E Michaelsen
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Authors:  S J Devi; W D Zollinger; P J Snoy; J Y Tai; P Costantini; F Norelli; R Rappuoli; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

7.  Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.

Authors:  W D Zollinger; E E Moran; S J Devi; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 8.  Molecular techniques for the investigation of meningococcal disease epidemiology.

Authors:  M C Maiden; M Frosch
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

9.  Variable region sequences and idiotypic expression of a protective human immunoglobulin M antibody to capsular polysaccharides of Neisseria meningitidis group B and Escherichia coli K1.

Authors:  F H Azmi; A H Lucas; H V Raff; D M Granoff
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

10.  Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.

Authors:  S J Devi; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.